Histamine N-methyltransferase upregulation, cardiac hypertrophy, and heart failure
HNMT exacerbates pathological hypertrophy and HF through SAM/FZD2/CaMKII axis. Amodiaquine, the inhibitor of HNMT, shows therapeutic potential against HF. Urinary N-methylhistamine emerges as a non-invasive HF biomarker.
Authors
- Kai Hu (ORCID: https://orcid.org/0000-0002-2900-2961)
- Yikai Cui
- Kun Liu (ORCID: https://orcid.org/0000-0001-5807-0501)
- Jing Yang (ORCID: https://orcid.org/0000-0001-9764-5136)
- Jinyan Zhang (ORCID: https://orcid.org/0000-0002-9874-2744)
- Xianhao Zhou
- Aijun Sun
- Liwei Liu (ORCID: https://orcid.org/0009-0003-3163-5586)
- Wenxuan Hong
- Zhuocong Xu
- Yu Song
- Lu Huang
- Jinfeng Gao
- Xin Li
- Xiaolei Sun
- Zhen Dong
- Yin Zhang
- Lei Xu
- Peng Wang
- Wei Luo
Institutions
- Bengbu Medical College (CN)
- Shanghai Jiao Tong University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Fudan University (CN)
- St. Francis Hospital (US)
- Shanghai Ninth People's Hospital (CN)
- Shanghai Xuhui Central Hospital (CN)
- National Clinical Research (US)
- Zhongshan Hospital (CN)
Publication Details
- Journal
- European Heart Journal
- Published
- 2025-12-13
- DOI
- https://doi.org/10.1093/eurheartj/ehaf1065
- Citations
- 1
- Primary Topic
- Mast cells and histamine
- Type
- article
- Field-Weighted Citation Impact
- 0.80